Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firms like Crown Castle and American Tower to secure at least 80,000 U.S. cell sites, driving their shares up. Wireless carriers AT&T, Verizon, and T-Mobile saw declines amid this news. Kohl's shares surged after receiving a rare Buy rating from an analyst optimistic about holiday sales. These developments highlight shifting investor sentiment across biotech, telecom infrastructure, and retail sectors.
As of Oct 23, 2026 18:02 WIB, Moderna (MRNA) shares are trading at USD 194.71 on Pluang, down 3.91% with 71% of orders being sell. Meanwhile, Crown Castle (CCI) and American Tower (AMT) are up 7.83% and 5.41% respectively, reflecting strong buying interest with 100% buy orders on Pluang. AT&T (T) shares have declined 4.49%, consistent with the sector's downward trend noted in the news.
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also de...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technolog...
